National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 5 of 10
A Test of Iron Malabsorption in Patients With Iron Deficiency Anemia
NCT00399191
Middle-School Based Primary Prevention Trial of Type 2 Diabetes
NCT00458029
Assessment of Beta Cell Mass in Type 1 Diabetes With 11C-Dihydrotetrabenazine and PET Scan
NCT00351650
Efficacy of Increasing Physical Activity to Reduce Children's Visceral Fat
NCT00359957
Gene Expression and Inflammation in Overweight Subjects
NCT00344266
Nutritional Intervention to Prevent Diabetes
NCT00333554
Statewide (Rhode Island and Neighboring States) Partnerships for Worksite Weight Management
NCT00288145
Study of Effects From Gastric Bypass Weight Loss on Brain Tissue
NCT00357344
Cinacalcet to Treat Familial Primary Hyperparathyroidism
NCT00325104
Low Magnitude Mechanical Stimuli Effects on Bone Structure in ESRD
NCT00364234
Effects of Caffeinated and Decaffeinated Coffee on Body Weight and Glucose Tolerance
NCT00305097
Stem Cell Collection
NCT00316069
Thyroid and Fat Tissue Metabolism
NCT00312715
Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver
NCT00323414
Efficacy & Safety Study of Pregabalin to Treat Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
NCT00371033
Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914
NCT00290251
Body Weight Regulation in Patients With Narcolepsy
NCT00283894
Frequent Hemodialysis Network: Daily Trial
NCT00264758
HALT Progression of Polycystic Kidney Disease Study B
NCT01885559
HALT Progression of Polycystic Kidney Disease Study A
NCT00283686
Kidney Disease Biomarkers
NCT00255398
Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
NCT00251316
A Randomized, Double-Blinded, Placebo-Controlled Trial of Corticosteroid Therapy Following Portoenterostomy
NCT00294684
Chronic Sleep Deprivation as a Risk Factor for Metabolic Syndrome and Obesity
NCT00261898
Assessment of Insulin Production From Native Pancreas in Patients With Pancreas Transplants
NCT00246844
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
NCT00063635
Iron Depletion Therapy for Type 2 DM and NAFLD
NCT00230087
Effect of Omega-3 PUFA Supplementation in NAFLD Patients
NCT00230113
Mechanisms of Diabetes Control After Weight Loss Surgery
NCT00571220
T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus
NCT00212329
Cognitive Effects of Bariatric Surgery
NCT00671775
Dietary Variety Versus Dietary Fat Effects in Energy Intake
NCT00285571
Myocardial Function & FFA Metabolism in HIV Metabolic Syndrome
NCT00656851
Does Metabolic Syndrome Exist in Anorexia Nervosa?
NCT00271921
Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation
NCT00135798
The Diabetes TeleCare Study
NCT00288132
Rituximab in New Onset Type 1 Diabetes
NCT00279305
SAMe to Treat Biliary Cirrhosis Symptoms
NCT00125281
Long-Term Lamivudine Therapy for Chronic Hepatitis B
NCT00120354
Obesity Assessment and Education Through the Internet
NCT00149682
A Trial of Two Diets for Weight and Diabetes Management
NCT00729196
Imuran Dosing in Crohn's Disease Study
NCT00113503
Use of Midlevel Providers in Diabetes Management
NCT00237094
Thyroid and Glucose and Energy Metabolism
NCT00106119
Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS)
NCT00124306
Development of Limited Contact CBT Treatment for IBS
NCT00248586
Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
NCT00103402
Internet Weight Control for Bingeing Adolescents
NCT00125112
Clinical and Laboratory Investigation of Humans With Informative Iron or Erythroid Phenotypes
NCT00102245
Exercise and Pioglitazone for HIV-Metabolic Syndromes
NCT00639457
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.